Literature DB >> 15017271

Role of glutamate receptors in the development and maintenance of bladder overactivity after cerebral infarction in the rat.

Osamu Yokoyama1, Hiroaki Mizuno, Kazuto Komatsu, Hironobu Akino, Kazuya Tanase, Mikio Namiki.   

Abstract

PURPOSE: To investigate the role of glutamate receptors in overactive bladder (OAB) caused by cerebral infarction (CI) we examined the effects of 2 different types of receptors antagonists on OAB induced by left middle cerebral artery (MCA) occlusion.
MATERIALS AND METHODS: Female rats were intravenously injected with dizocilpine, an NMDA (N-methyl-D-aspartate) receptor antagonist, or NBQX (2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-sulfonamide), an AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist, before or after MCA occlusion. Awake rats were cystometrically examined for 8 hours. Detrusor strips were evaluated for force development in response to dizocilpine and NBQX.
RESULTS: In CI rats without pretreatment bladder capacity (BC) was significantly decreased after MCA occlusion and remained consistently below half that of pre-occlusion capacity. Dizocilpine (0.5 mg/kg intravenously) administered before MCA occlusion blocked the decrease in BC in awake rats 5 to 8 hours after MCA occlusion. In CI rats pretreated with NBQX (10 or 30 mg/kg intravenously) BC was not different from that in rats without pretreatment. Increasing doses of dizocilpine (0.01 to 10 mg/kg) or NBQX (0.1 to 30 mg/kg) increased rat BC 2 hours after MCA occlusion. NBQX did not change the BC of sham operated rats. No differences in the contractile response to dizocilpine or NBQX of detrusor strips from sham operated and CI rats were observed.
CONCLUSIONS: These results indicate that NMDA receptor has an essential role in the development of OAB after CI. AMPA receptor antagonist cannot block the development of OAB. However, AMPA receptor antagonist temporally inhibits OAB after it is established by CI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15017271     DOI: 10.1097/01.ju.0000104861.73314.fe

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  Neural control of the lower urinary tract.

Authors:  William C de Groat; Derek Griffiths; Naoki Yoshimura
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

2.  Inhibition of NMDAR reduces bladder hypertrophy and improves bladder function in cyclophosphamide induced cystitis.

Authors:  Miao Liu; Shanwei Shen; Derek M Kendig; Sunila Mahavadi; Karnam S Murthy; John R Grider; Li-Ya Qiao
Journal:  J Urol       Date:  2015-01-06       Impact factor: 7.450

Review 3.  The effect of amino acids on the bladder cycle: a concise review.

Authors:  Özer Ural Çakıcı; Sibel Dinçer
Journal:  Amino Acids       Date:  2021-12-01       Impact factor: 3.520

4.  NMDAR in bladder smooth muscle is not a pharmacotherapy target for overactive bladder in mice.

Authors:  Xiang Xie; Chuang Luo; Jia Yu Liang; Run Huang; Jia Li Yang; Linlong Li; YangYang Li; Hongming Xing; Huan Chen
Journal:  PeerJ       Date:  2021-07-07       Impact factor: 2.984

5.  Expression of prostate-specific membrane antigen in normal and malignant human tissues.

Authors:  Yoshihisa Kinoshita; Katsuyuki Kuratsukuri; Steve Landas; Katsumi Imaida; Peter M Rovito; Ching Y Wang; Gabriel P Haas
Journal:  World J Surg       Date:  2006-04       Impact factor: 3.282

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.